NICE Sends Out Cost Warning By Flatly Rejecting Kadcyla On Price
This article was originally published in The Pink Sheet Daily
Executive Summary
Not inspired by its clinical effectiveness, NICE has said it will not recommend Roche's “over-priced” Kadcyla for breast cancer.